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ABSTRACT Suppression of the SOS response has been postulated as a therapeutic
strategy for potentiating antimicrobial agents. We aimed to evaluate the impact of
its suppression on reversing resistance using a model of isogenic strains of Esche-
richia coli representing multiple levels of quinolone resistance. E. coli mutants exhib-
iting a spectrum of SOS activity were constructed from isogenic strains carrying quino-
lone resistance mechanisms with susceptible and resistant phenotypes. Changes in
susceptibility were evaluated by static (MICs) and dynamic (killing curves or flow cy-
tometry) methodologies. A peritoneal sepsis murine model was used to evaluate in
vivo impact. Suppression of the SOS response was capable of resensitizing mutant
strains with genes encoding three or four different resistance mechanisms (up to 15-
fold reductions in MICs). Killing curve assays showed a clear disadvantage for sur-
vival (Δlog10 CFU per milliliter [CFU/ml] of 8 log units after 24 h), and the in vivo ef-
ficacy of ciprofloxacin was significantly enhanced (Δlog10 CFU/g of 1.76 log units) in
resistant strains with a suppressed SOS response. This effect was evident even after
short periods (60 min) of exposure. Suppression of the SOS response reverses anti-
microbial resistance across a range of E. coli phenotypes from reduced susceptibility
to highly resistant, playing a significant role in increasing the in vivo efficacy.
IMPORTANCE The rapid rise of antibiotic resistance in bacterial pathogens is now
considered a major global health crisis. New strategies are needed to block the de-
velopment of resistance and to extend the life of antibiotics. The SOS response is a
promising target for developing therapeutics to reduce the acquisition of antibiotic
resistance and enhance the bactericidal activity of antimicrobial agents such as quin-
olones. Significant questions remain regarding its impact as a strategy for the rever-
sion or resensitization of antibiotic-resistant bacteria. To address this question, we
have generated E. coli mutants that exhibited a spectrum of SOS activity, ranging
from a natural SOS response to a hypoinducible or constitutively suppressed re-
sponse. We tested the effects of these mutations on quinolone resistance reversion
under therapeutic concentrations in a set of isogenic strains carrying different com-
binations of chromosome- and plasmid-mediated quinolone resistance mechanisms
with susceptible, low-level quinolone resistant, resistant, and highly resistant pheno-
types. Our comprehensive analysis opens up a new strategy for reversing drug resis-
tance by targeting the SOS response.
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Efforts to overcome the problem of resistance have focused mainly on modifyingexisting antibiotics by circumventing the molecular mechanisms conferring resis-
tance (1). While such efforts are efficacious against resistant strains, new resistance
mechanisms often arise in the process of adaptation to new antimicrobial agents (2, 3).
Members of the Enterobacteriaceae family, like Escherichia coli, are among the most
common causes of community and nosocomial infections. Fluoroquinolones are used
for empirical and directed therapy in infections caused by E. coli (4). Quinolone
resistance has increased notably in Enterobacteriaceae from both human and veterinary
isolates (5, 6). Mechanisms of fluoroquinolone resistance occur principally through
chromosomal mutations in genes encoding the quinolone targets (DNA gyrase and
topoisomerase IV), and to a lesser extent through decreased permeability (6). Plasmid-
mediated quinolone resistance mechanisms have also been described (7). These de-
terminants on their own (whether chromosomally or plasmid mediated) confer low-
level quinolone resistance (LLQR), so that multiple mechanisms must be combined to
achieve clinical resistance.
New strategies are needed to block the development of resistance and to extend
the life of antibiotics such as quinolones. Multiple studies suggest that adaptive
resistance mutations and the acquisition of resistance genes by bacteria are induced or
facilitated by antibiotic therapy due to the activation of RecA (leading to the SOS
response, the DNA repair and mutagenesis pathway) (8–10). Antibiotics can trigger
bacterial stress at both lethal and sublethal concentrations (8). In this respect, fluoro-
quinolones are potent inducers of the SOS response, causing DNA damage or arresting
replication forks by blocking DNA gyrase (10, 11). The SOS pathway is initiated through
the activation of RecA, which in turn induces autocatalytic cleavage of the LexA
repressor and induces the SOS response genes (8, 10). RecA is involved in DNA repair,
recombination, induction of the SOS response, horizontal gene transfer, and biofilm
formation (10, 12–14). Systematically altering bacterial SOS activity, both constitutive
SOS activation and inactivation, has been revealed as a therapeutic strategy for
potentiating bactericidal antibiotics like quinolones against highly susceptible wild-
type E. coli (15, 16). Several compounds have also been shown to inhibit the ATPase
activity of RecA in vitro (17–19). Phthalocyanine tetrasulfonate were recently charac-
terized as an in vivo RecA inhibitor (20). In short, the SOS response is a promising target
for developing therapeutics to enhance the bactericidal activity of antimicrobial agents
such as quinolones.
Despite genetic data implicating the SOS response as critical to the survival and
adaptation of highly susceptible wild-type bacteria, significant questions remain re-
garding its impact as a strategy for the reversion or resensitization of antibiotic-resistant
bacteria under therapeutic concentrations (21–23). To address this question, we gen-
erated E. coli mutants that exhibited a spectrum of SOS activity, ranging from a natural
SOS response to a hypoinducible (LexA1; very low cleavage rate) (24) or constitutively
suppressed response (ΔrecA) (Fig. 1). We tested the effects of these mutations on a set
of isogenic strains carrying different combinations of chromosome- and plasmid-
mediated quinolone resistance mechanisms with susceptible, LLQR, resistant, and
highly resistant phenotypes. Our comprehensive analysis opens up a new strategy for
reversing drug resistance by targeting the SOS response.
(This study was presented in part at ASM Microbe, Boston, MA, in 2016 [oral
presentation, session 374].)
RESULTS
Suppression of the SOS response sensitizes fluoroquinolone resistance. Six
isogenic E. coli strains harboring frequent chromosomal mutations, associated with
fluoroquinolone resistance, in the gyrA and/or parC genes and/or a deletion in the marR
gene and combined with plasmid-mediated quinolone resistance (PMQR) mechanism
(qnrS) (ranging from wild-type high level of susceptibility to a high level of resistance)
were used for recA deletion or lexA replacement by lexA1 and evaluated for suscepti-
bility to quinolones (Table 1; also see Table S1A in the supplemental material).
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We first confirmed that the ΔrecA and lexA1 mutations produce the expected
perturbations in the SOS response (significant differences were observed confirming
suppression and hypoinduction of the SOS response, respectively) (Fig. S1). The reduc-
tions in the MICs of ciprofloxacin ranged from 1-fold to 8-fold against both the ΔrecA
and LexA1 strains (Table 1). Sensitization was greater in ΔrecA strains (with constitutive
SOS inactivation), ranging from 4-fold to 8-fold (Table 1; Fig. S2). Of note, the
EC04lexA1 strain did not reduce the MIC values of most the quinolones, which lends
support to the hypoinducible SOS response as a less effective strategy of sensitization
to quinolones. The process of sensitization was equally efficient across susceptible,
LLQR, and resistant phenotypes and independent of the type of molecular mechanism
involved in quinolone resistance or whether it was chromosomally or plasmid medi-
ated. Interestingly, recA inactivation in the EC02 strain (carrying a GyrA protein with
S83L substitution) modified the ciprofloxacin MIC value below the epidemiological
cutoff (0.032 mg/liter) (http://www.eucast.org) (25). Here we show that, in terms of
MICs, SOS inactivation suppresses the effects of first-step mutations toward resistance
associated with topoisomerase type II modifications.
Similar results were observed for all quinolones tested. The MICs were reduced up
to 8-, 8-, 15-, 4-, 4-, and 2-fold for ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin,
ofloxacin, and nalidixic acid, respectively (Table S1A).
In addition, the changes in the ciprofloxacin MICs observed for EC08 (MIC of
2 mg/liter down to 0.5 mg/liter) and EC09 (MIC of 8 mg/liter down to 1 mg/liter) recA
deficient strains involved changes to the susceptible category. Here, strain EC08, which
is intermediate or resistant according to the CLSI and EUCAST breakpoints, respectively,
was sensitized to susceptible according to both committees. Similarly, the resistant
strain, EC09, was sensitized to susceptible and intermediate-susceptible according to
the CLSI and EUCAST breakpoints, respectively (Table 1). The clinical category was also
changed to susceptible against levofloxacin and moxifloxacin (Table S1A).
These data all lend support to suppression of the SOS response as capable of
resensitizing mutant strains with genes encoding three, or even four, different mech-
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FIG 1 Engineered recA and lexA variants in E. coli displaying a range of SOS activities. The LexA protein is represented by
green ovals, and lexA1 (G80D) cleavage mutations are labeled in orange. RecA is shown as red filaments, and recA deleted
mutants are labeled in red. Strains with a natural SOS response are labeled in green. Four lexA1 mutants and six mutants
with recA deleted were derived from low-level quinolone-resistant (LLQR), resistant, and high-level resistant wild-type (WT)
phenotypes of quinolone resistance, allowing the bacterial response to quinolones to be examined across a spectrum of
SOS activity. Activated RecA filaments led to cleavage of LexA and inducible expression of SOS genes in the WT strain.
Deletion of recA (ΔrecA) inactivated the SOS response. Mutations in the LexA protein (G80D) reduce the rate of
self-cleavage relative to the WT strain and so affect the level of SOS induction.
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anisms of acquired quinolone resistance. The degree of sensitization could be consid-
ered moderate (up to 15-fold).
SOS suppression enhances bactericidal activity against resistant strains. To
show the impact of SOS response suppression in terms of bacterial viability, time-kill
curves were obtained for each isogenic group according to the SOS system induction
status. At fixed concentrations, a marked reduction of viable bacteria was observed
with the inactivated SOS response over 24 h of incubation (Fig. 2). At 1 mg/liter, a
bactericidal effect (drop of 3 log10 CFU/ml) was observed against strain EC08recA
after 4 h (and no viable bacteria were recovered after 6 h). At 2.5 mg/liter, a bactericidal
effect was observed against both EC08 (after 4 h) and EC08recA (after 2 h), although
regrowth was observed after 24 h in strain EC08 (6.8 log10 CFU/ml) but not strain
EC08recA (Fig. 2). At 1 mg/liter, a bacteriostatic effect only (drop of 3 log10 CFU/ml)
was observed in strain EC09recA (although a marked difference was observed in the
first 8 h compared to EC09, up to Δ4.2 log10 CFU/ml at 6 h). At 2.5 mg/liter, however,
a bactericidal effect was observed in EC09recA (after 2 h) and a bacteriostatic effect in
EC09 in the first 8 h, with regrowth after 24 h (Fig. 2). Under these conditions, SOS
induction suppression leads to a high bactericidal effect under relevant therapeutic
concentrations in E. coli harboring multiple mechanisms of quinolone resistance.
At 1 MIC of ciprofloxacin (of the tested strains harboring a nonmodified SOS
system), major differences in the numbers of viable bacteria were observed after 24 h
(Δ6.1, Δ4.2, Δ9.5, and Δ6.9 log10 CFU/ml in the ATCC, EC04, EC08, and EC09 isogenic
pairs, respectively). Minor differences were observed at 4 MIC of ciprofloxacin
(Fig. S3). Additional kinetic assays (growth curves and ATP production) confirmed these
results (Fig. S8).
Suppression of SOS response reduces survival in resistant strains after a short
time. The LIVE/DEAD staining method was tested using three different approaches to
show the impact of SOS inactivation on bacterial survival during a short period of









referencegyrA1 gyrA2 parC marR qnr SOS system
ATCCe WTf 0.008 S/S Lab collection
ATCCrecA ΔrecA 0.002 S/S 4 This study
ATCClexA1 lexA1 0.004 S/S 2 This study
EC02 S83L WT 0.25 S/S 31
EC02recA S83L ΔrecA 0.03 S/S 8 This study
EC04 S83L S80R WT 0.5 S/S 31
EC04recA S83L S80R ΔrecA 0.125 S/S 4 This study
EC04lexA1 S83L S80R lexA1 0.5 S/S 1 This study
EC08 S83L D87N S80R WT 2 I/R 31
EC08recA S83L D87N S80R ΔrecA 0.5 S/S 4 This study
EC09 S83L D87N S80R ΔmarR WT 8 R/R 31
EC09recA S83L D87N S80R ΔmarR ΔrecA 1 S/I 8 This study
EC09lexA1 S83L D87N S80R ΔmarR lexA1 2 I/R 4 This study
EC59 S83L D87N S80R ΔmarR qnrS WT 32 R/R 31
EC59recA S83L D87N S80R ΔmarR qnrS ΔrecA 4 R/R 8 This study
EC59lexA1 S83L D87N S80R ΔmarR qnrS lexA1 32 R/R 1 This study
aStrains are isogenic to E. coli ATCC 25922 and carry only the chromosomal modifications, qnrS gene, and/or SOS dysfunction (recA deletion or nonproteolizable LexA
variant [LexA1]). Resistance-associated mutations located in the GyrA and ParC proteins have been defined as resistance mechanisms that alter the target site.
bMIC (in milligrams per liter) of ciprofloxacin by Etest.
cCC, clinical category according to the CLSI and EUCAST breakpoints (25, 38). The clinical category according to the CLSI breakpoint is shown before the slash, and
the clinical category according to the EUCAST breakpoint is shown after the slash. The clinical categories are shown as follows: S, susceptible; I, intermediate
susceptibility; R, resistant. Subgroups with clinical category changes are indicated in boldface type.
dFold reduction of MIC compared to the MIC of wild-type strain for the SOS system in each isogenic subgroup.
eE. coli ATCC 25922.
fWT, wild-type.
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exposure to quinolones. First, using the Infinite 200PRO multireader, it was clear that
the live/dead ratio depended significantly on the SOS response functionality. Fig-
ure S4A shows the quantitative results obtained at 1 MIC of ciprofloxacin (according
to the MICs of strains with a functional SOS response) after 4 h of exposure. Under these
conditions, the ratio of live to dead cells for E. coli ATCCrecA, EC04recA, EC08recA, and
EC09recA deficient SOS variants decreased by 88%, 94%, 98%, and 98%, respectively,
compared to their parental variants with the wild-type SOS response (P  0.001). This
reduction was also proportional to the level of quinolone resistance (P  0.001).
Second, these results were supported by fluorescence microscopy assay. Figure S4A
shows representative images of strains EC08 and EC08recA exposed to 2.5 mg/liter
(maximum concentration of drug in serum [Cmax]) of ciprofloxacin for 4 h, supporting
the differential response. Third, in order to determine whether the SOS response was
a key factor for survival after a very short period of exposure to bactericidal drugs like
quinolones in strains with mechanisms of acquired resistance (strains EC02, EC04, EC08,
and EC09), flow cytometry was used to examine bacterial viability after 60 min of
exposure at multiple concentrations of ciprofloxacin (see Materials and Methods). A
significant reduction in cell viability was observed following treatment with ciprofloxa-
cin at 4 MIC and 2.5 mg/liter (Fig. 3 and S4B) (also at 1 MIC and 1 mg/liter [data not
shown]), which correlates directly with the inability to activate the SOS response. These
results imply that the SOS response is a key short-term responder to DNA damage in
both LLQR and resistant E. coli at clinically relevant quinolone concentrations.
Pharmacokinetics and pharmacodynamics of the in vivo model. The fit of the
mathematical model to the mouse serum data (i.e., correlation between the observed
Time (hours)
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FIG 2 SOS inactivation enhances bactericidal activity against resistant strains. Viable bacterial counts of the EC08/EC08recA and EC09/EC09recA isogenic pairs
in time-kill assays at ciprofloxacin (CIP) concentrations of 1 mg/liter (breakpoint for resistance according to EUCAST) and 2.5 mg/liter (human serum Cmax),
respectively. Data are represented as the means from at least three independent measurements. Standard deviations are indicated by the error bars (standard
deviations not shown are smaller than the symbols).
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versus predicted data of the mathematical model) was acceptable (R2  0.968). The
estimated parameter values were as follows: clearance (CL), 0.38  101 liters/h;
volume of distribution of the drug in the peripheral compartment (Vp) of 0.95 
102 liters; transfer rate constant from central to peripheral compartment (kcp) of 4.03;
transfer rate constant from peripheral to central compartment (kpc)  0.44 107
(Fig. S5). AUC/MIC values of 12.2/24.4 for strain EC08 and 48.8/97.6 for strain EC08recA
were predicted in our model for 50 and 100 mg/kg of body weight, respectively.
SOS suppression enhances bactericidal activity against resistant strains in vivo.
Selected isogenic mutants, ciprofloxacin-nonsusceptible strain EC08 and susceptible
strain EC08ΔrecA, were included in a murine model of intraperitoneal sepsis. No
differences of bacterial load were observed in the spleens of control groups infected
with strains EC08 and EC08ΔrecA (7.73  0.62 versus 7.45  0.61 log10 CFU/g). All the
controls died in the first 48 h according to the minimum lethal dose (MLD), with no
differences between the strains (P  0.05). Note that 33% mortality was observed
within the first 24 h in the EC08 group treated with 50 mg/kg every 12 h (q12h), while
no mortality was observed in the remaining treated groups during the experiments.
With respect to bacterial burden, in mice infected with strain EC08ΔrecA (with the
inactivated SOS response), treatment with ciprofloxacin at 50 mg/kg q12h and at
100 mg/kg q12h significantly reduced bacterial concentrations (Δlog10 CFU/g units of
1.75 and 1.76 in the spleen; P  0.001, respectively) with respect to groups infected
with strain EC08 (with the active SOS response) (Fig. 4).
DISCUSSION
The SOS response plays an important role in adaptation and acquired bacterial
resistance to antibiotics. The key regulators (LexA and RecA) have been proposed as an
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A B
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FIG 3 Flow cytometry of four groups of isogenic LLQR cells (harboring a natural [wild-type] or inactive SOS system [ΔrecA]) treated for 60 min at 2.5 mg/liter
or at 4 MIC (relative to the MIC of the wild-type SOS) of ciprofloxacin. Survival was measured as staining with green fluorescent SYTO9.Strains EC02 (A), EC04
(B), EC08 (C), and EC09 (D) were studied.
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emergence of resistance. This strategy has been tested essentially against highly
susceptible wild-type bacteria without molecular mechanisms of acquired resistance
(16, 26–28). Low-level resistance phenotypes, such as LLQR (which can be exposed to
sublethal levels of antibiotics during antimicrobial treatment), pose a significant threat
to the development of clinical resistance (29–31). Previous data validating the SOS
response as a target of interest motivated our efforts to explore the consequences of
a broader spectrum of SOS activity, ranging from natural through hypoinducible to
constitutively repressed SOS response (Fig. 1) in a set of isogenic strains carrying
combinations of chromosome- and plasmid-mediated quinolone resistance, and phe-
notypes ranging from susceptible to LLQR, resistant, and highly resistant. Our detailed
analysis opens up a new strategy for reversing drug resistance by targeting the SOS
response.
The bactericidal activity of quinolones in bacteria has been related to a combination
of DNA fragmentation, reactive oxygen species (ROS) production, and pro-
grammed cell death systems, such as mazEF (32–35). The SOS response has also
been postulated as a formidable strategy against aggressions such as antimicrobial
exposure (10). The link between quinolones, activation of the SOS response, and
induction of antibiotic resistance (26, 28) demonstrates the potential for reducing
resistance by targeting the RecA and LexA proteins that are essential for an SOS
response. Our study provides evidence that suppression of the SOS pathway can
synergize with specific antimicrobial agents, such as quinolones, to reduce MICs in
a process of resistance reversion. In the case of constitutive SOS inactivation, the
MIC data of ΔrecA mutants were in agreement with earlier studies of highly
susceptible wild-type phenotypes (36, 37), and resensitization was observed in
LLQR, resistant, and highly resistant phenotypes (Table 1 and Fig. 2 and 4; also see
Fig. S6 in the supplemental material). However, the increased sensitivity was less
when the level of SOS induction was attenuated by a slow-cleaving LexA variant,





























































































FIG 4 SOS inactivation reduces the in vivo survival of mice infected with bacteria receiving quinolone
treatment. Efficacies of ciprofloxacin (CIP) in a murine model of sepsis caused by strains EC08 (intact SOS
system) and EC08recA (inactivated SOS system). Group 1 was given ciprofloxacin 50 mg/kg q12h
intraperitoneally. Group 2 was given ciprofloxacin 100 mg/kg q12h intraperitoneally. The control group
was not treated with ciprofloxacin. Standard deviations are indicated by the error bars. Values that were
significantly different (P  0.001) are indicated by a bar and asterisk. Values that were not significantly
different (ns) are indicated.
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and resistant phenotypes. This discrepancy could be due, in part, because recA
deletion can have an impact beyond leading to loss of LexA cleavage and SOS
response suppression, with additional implications in important processes like
homologous recombination. An overactive SOS response can also increase quino-
lone susceptibility, although to a lesser extent than constitutive inhibition (15).
Moreover, several compounds that inhibit RecA in vitro or in vivo have been
discovered (17–20). In short, potent inhibition of the SOS response in concert with
DNA-damaging agents like quinolones offers the best option for potential synergy,
and we focused our study on recA mutants in order to show their impact on the
reversion of quinolone resistance.
According to the CLSI guidelines (38), complete inactivation of the SOS response led
to a change in clinical category for ciprofloxacin from intermediate or resistant to
susceptible in EC08 (S83L, D87N, and S80R substitutions) and EC09 (S83L, D87N, and
S80R substitutions and ΔmarR) strains, respectively. Using EUCAST guidelines (25),
inactivation changed the clinical category from resistant to susceptible in strain EC08
and to intermediate-susceptible in strain EC09, respectively. These results support the
relevance of a strategy of SOS inactivation for bringing about reversion of antimicrobial
resistance at a level that could be clinically significant. Interestingly, the inactivation of
recA in the EC02 strain (encoding an S83L substitution) modified the ciprofloxacin MIC
below the epidemiological cutoff (0.032 mg/liter; http://www.eucast.org) (39, 40). Here
we show that inactivation of the SOS system suppresses the effect, in terms of MIC,
of the first step toward resistance associated with topoisomerase type II modifica-
tions. A qualitative model illustrating the efficacy of SOS suppression in the
resensitization of quinolone resistance is shown in Fig. 5, showing that this phe-
nomenon is observed in bacteria with genes encoding multiple (up to four) different
resistance mechanisms.
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FIG 5 A general qualitative model illustrating the efficacy of SOS response suppression for reversion of
fluoroquinolone resistance. Reversion of resistance was even observed in bacteria carrying genes encoding
four different resistance mechanisms. Red bars correspond to E. coli with an intact SOS system; green bars
correspond to E. coli with a suppressed SOS response. The epidemiological cutoff (ECOFF) (0.032 mg/liter
[http://www.eucast.org]) is indicated by the red dotted line. S, I, and R mean susceptibility, intermediate
susceptibility, and clinical resistance, respectively. SOS- means SOS response suppression.
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reversion of quinolone resistance mediated by an inactivated SOS response at both
long and short periods of exposure to drugs. In all cases, we observed a clear selective
disadvantage for survival in strains with a suppressed SOS response when exposed to
ciprofloxacin at relevant concentrations (breakpoint concentrations, serum Cmax, and
MIC values) (Fig. 2 and 3 and S6). For time-kill curves, an inactivated SOS response in
E. coli harboring multiple mechanisms of resistance had a high bactericidal effect in the
presence of clinically relevant ciprofloxacin concentrations after 2 to 4 h of exposure
(depending on the strain and conditions), which was maintained for 24 h (Fig. 2 and S3).
Flow cytometry assays also showed significant reductions in cell viability following a
short period of exposure to the drug (60 min), which was directly related to the inability
to activate the SOS response (Fig. 3). Our data show that changes in the MICs of specific
quinolone-resistant strains (EC08 and EC09) as a result of an inactivated SOS response
correlated with ROS formation at clinically relevant concentrations of ciprofloxacin
(Fig. S7). In terms of bacterial viability, these data support the potential utility of this
strategy for resensitizing or reversing quinolone resistance after both short and long
periods of exposure to quinolones at relevant concentrations. Interestingly, whether
SOS response suppression could restrict the evolution to clinical resistance in LLQR
phenotypes should be tested (16).
Although SOS response inactivation led to moderate reductions in the MICs of
ciprofloxacin (up to 8-fold) and other fluoroquinolones (up to 15-fold), these differences
could play a significant role in therapeutic failure, bearing in mind the concentration-
dependent character of these antimicrobials, whose predictors of efficacy in vivo are
Cmax/MIC and AUC/MIC. AUC/MIC values of 30 are associated with low mortality and
are required for clinical efficacy (41–44). Our murine sepsis model, using isogenic strains
that were resistant (EC08) and susceptible (EC08recA; lacking SOS response) to cipro-
floxacin according to EUCAST, showed the impact of the pathway on the in vivo efficacy
of this fluoroquinolone (with a reduction in bacterial count of around 99%). Our murine
model shows that inactivation of the SOS pathway in an initially quinolone-resistant
E. coli strain (EC08) significantly increases the in vivo efficacy of ciprofloxacin. According
to our data, engineered bacteriophage targeting SOS response (by overexpression of
an inactivated LexA variant) was shown to be a promising resistance reversion strategy
(45).
In overall terms, this study shows that suppression of the SOS response enhances
the bactericidal activity of antimicrobials like quinolones across a range of E. coli
phenotypes from highly susceptible to highly resistant and plays a significant role in
increasing the in vivo efficacy of these bactericidal drugs against bacteria with multiple
mechanisms of acquired resistance. The development of RecA inhibitors could function
as an adjuvant therapy, potentiating antimicrobial activity and contributing to the
resensitization or reversion of drug resistance.
MATERIALS AND METHODS
Strains, growth conditions, and antimicrobial agents. Wild-type E. coli ATCC 25922 was used as
the starting strain for all constructions (Table 1). E. coli ATCC 25922 (wild-type) and isogenic EC02, EC04,
EC08, EC09, and EC59 strains represent progressive degrees of fluoroquinolone resistance, ranging from
susceptible to resistant (see Text S1 in the supplemental material for details).
Liquid or solid Luria-Bertani medium (LB), Mueller-Hinton broth (MHB), and M9 minimal medium
were used. Strains were grown at 37°C. The following quinolones were used for the different assays:
nalidixic acid, ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, and ofloxacin (Sigma-Aldrich, Madrid,
Spain).
Isogenic strain construction. lexA1 mutants (coding for a LexA G80D substitution) (46) were
obtained by gene replacement, as previously described (Table 1 and see Table S1B in the supplemental
material) (31, 47). Disruption of the recA gene was carried out with a modified version of the method
described by Datsenko and Wanner (48). The qnrS gene was cloned into the pBK-CMV vector as described
previously (31) (see Text S1 for details).
MICs. MICs were determined in triplicate for each bacterial strain, using two different techniques,
broth microdilution and the Etest technique, and following CLSI reference methods (38). Clinical
categories were established according to CLSI and EUCAST breakpoints (25, 38).
Time-kill curve assays. To show the effect of suppression of the SOS response on bacterial viability,
time-kill assays were performed with each isogenic group based on the SOS system induction status.
Mueller-Hinton broth was used with 1 MIC and 4 MIC concentrations of ciprofloxacin. Ciprofloxacin
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concentrations were relative to MICs for strains harboring the unmodified SOS system (i.e., with intact
recA and lexA genes). Selected isogenic groups of strains, the EC08 and EC09 groups (bordering on
clinical resistance) were also exposed to fixed concentrations of antimicrobial (1 mg/liter, the breakpoint
for resistance according to EUCAST, or 2.5 mg/liter, human serum Cmax for ciprofloxacin) in MHB (25, 49).
Growth in drug-free broth was evaluated in parallel as a control. Cultures were incubated at 37°C with
shaking at 250 rpm. An initial inoculum of 106 CFU/ml was used in all experiments, and bacterial
concentrations were determined at 0, 2, 4, 6, 8, and 24 h by colony counting.
Quantification of live/dead bacteria by flow cytometry. The Molecular Probes LIVE/DEAD BacLight
bacterial viability kit (Invitrogen) was used to show the impact of SOS inactivation after a short period
of antimicrobial exposure by flow cytometry (Cytomics FC500-MPL; Beckman Coulter) according to the
kit instructions.
Cells were exposed at 1 MIC and 4 MIC ciprofloxacin concentration of the tested strains harboring
a nonmodified SOS system (i.e., intact recA and lexA genes) or to a fixed concentration (1 mg/liter, the
breakpoint for resistance according to EUCAST, or 2.5 mg/liter, the serum Cmax for ciprofloxacin) (25, 49).
Cells were cultured in the same way and exposed to ciprofloxacin for 60 min. To prepare the cells for
measurement, 1 ml of cell culture was washed once in ice-cold phosphate-buffered saline (PBS),
resuspended in 1 ml of saline solution, stained according to the kit instructions, and then incubated for
15 min before counting. The following photomultiplier tube (PMT) voltages were used: 420 V for FL1 and
560 V for FL3. At least 10,000 cells per sample were collected. Flow cytometry acquisition was performed
at a low flow rate (~30 events/s) (35).
Mice. Male immunocompetent C57BL/6 mice were obtained from the University of Seville. The
project was approved by the Ethics and Clinical Research Committee of the Virgen Macarena and Virgen
del Rocio University Hospitals (reference number 1086-N-15) (see Text S1 for details).
Pharmacokinetics and pharmacodynamics. Pharmacokinetic serum data from our previous work
were fitted to a two-compartment model (intraperitoneal space and blood) using ADAPT 5 (50, 51). A
range of dosages were simulated in order to obtain a favorable pharmacokinetic parameter of area under
the concentration-time curve from 0 to 24 h (AUC024)/MIC ~50 or ~100, adjusted to the SOS-deficient
strain in the isogenic pair EC08/EC08recA (strain EC08recA has a ciprofloxacin MIC of 0.5 mg/liter).
Experimental model. Mice weighing 16 to 18 g were used. Using a murine model of peritoneal
sepsis, the minimum lethal dose (MLD) for EC08 and EC08recA strains was determined (see Text S1 for
details). The murine model was used to evaluate the efficacy of ciprofloxacin between strains EC08 and
EC08recA. Mice were infected intraperitoneally using the MLD. Two hours postinfection, antimicrobial
therapy started. Animals were randomly assigned to different therapeutic groups as follows: group
1,ciprofloxacin administered intraperitoneally at 50 mg/kg of body weight every 12 h (q12h); group 2,
ciprofloxacin administered intraperitoneally at 100 mg/kg q12h;control group, no ciprofloxacin treat-
ment. At 24 h, the bacterial loads in the spleens of 15 mice per strain and ciprofloxacin dosage were
determined (see Text S1 for details).
Statistical analysis. For statistical evaluation, the Student’s t test was used when two groups were
compared. The analysis of variance (ANOVA) test and Tukey’s posthoc tests were used for group
comparisons. Differences were considered significant when P values were 0.05.
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